Everence Capital Management Inc. bought a new stake in Omnicell, Inc. (NASDAQ:OMCL) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 2,840 shares of the company’s stock, valued at approximately $204,000.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in OMCL. BlackRock Inc. lifted its stake in shares of Omnicell by 14.1% in the second quarter. BlackRock Inc. now owns 5,575,352 shares of the company’s stock valued at $292,428,000 after buying an additional 690,464 shares during the period. Janus Henderson Group PLC lifted its stake in Omnicell by 52.1% during the second quarter. Janus Henderson Group PLC now owns 1,513,979 shares of the company’s stock worth $79,408,000 after purchasing an additional 518,824 shares during the period. Copper Rock Capital Partners LLC bought a new position in Omnicell during the third quarter worth about $32,606,000. Paradigm Capital Management Inc. NY bought a new position in Omnicell during the second quarter worth about $22,202,000. Finally, Carillon Tower Advisers Inc. lifted its stake in Omnicell by 208.9% during the second quarter. Carillon Tower Advisers Inc. now owns 500,403 shares of the company’s stock worth $26,246,000 after purchasing an additional 338,403 shares during the period. Institutional investors and hedge funds own 98.80% of the company’s stock.
NASDAQ OMCL opened at $69.70 on Wednesday. The company has a market cap of $2.72 billion, a PE ratio of 387.22, a PEG ratio of 4.14 and a beta of 0.98. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.78 and a quick ratio of 1.32. Omnicell, Inc. has a 1-year low of $39.75 and a 1-year high of $73.00.
In related news, CFO Peter J. Kuipers sold 5,574 shares of the firm’s stock in a transaction that occurred on Monday, September 10th. The shares were sold at an average price of $68.87, for a total value of $383,881.38. Following the completion of the sale, the chief financial officer now owns 51,542 shares of the company’s stock, valued at $3,549,697.54. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Dan S. Johnston sold 6,250 shares of the firm’s stock in a transaction that occurred on Monday, October 15th. The shares were sold at an average price of $63.47, for a total transaction of $396,687.50. Following the completion of the sale, the executive vice president now directly owns 35,996 shares of the company’s stock, valued at approximately $2,284,666.12. The disclosure for this sale can be found here. In the last three months, insiders sold 24,277 shares of company stock valued at $1,654,248. 3.71% of the stock is currently owned by company insiders.
A number of brokerages have commented on OMCL. Wells Fargo & Co raised their price target on shares of Omnicell from $59.00 to $61.00 and gave the stock a “market perform” rating in a research note on Monday, October 29th. Oppenheimer raised their price target on shares of Omnicell from $71.00 to $73.00 and gave the stock an “outperform” rating in a research note on Friday, October 26th. Cantor Fitzgerald raised their price target on shares of Omnicell from $63.00 to $70.00 and gave the stock an “overweight” rating in a research note on Friday, October 26th. MED raised their price objective on shares of Omnicell from $59.00 to $71.00 and gave the stock an “in-line” rating in a report on Monday, October 22nd. Finally, Benchmark raised their price objective on shares of Omnicell from $66.00 to $79.00 and gave the stock a “buy” rating in a report on Friday, October 5th. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $69.86.
TRADEMARK VIOLATION WARNING: This piece was reported by Enterprise Leader and is the property of of Enterprise Leader. If you are accessing this piece on another site, it was copied illegally and republished in violation of United States and international copyright and trademark law. The original version of this piece can be accessed at https://theenterpriseleader.com/2018/11/07/everence-capital-management-inc-purchases-new-position-in-omnicell-inc-omcl.html.
Omnicell, Inc provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications.
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.